HARMONY BIOSCIENCES HLDG INC (HRMY)
Sector: Health Care
2026 Annual Meeting Analysis
HARMONY BIOSCIENCES HLDG INC · Meeting: May 14, 2026
Directors FOR
3
Directors AGAINST
1
Say on Pay
AGAINST
Auditor
FOR
Director Elections
Election of Four Class III Directors to Serve Until the 2029 Annual Meeting of Stockholders
Against Analysis
Dr. Wicki has served on the board since 2017 and therefore his tenure fully overlaps the period during which Harmony's stock fell roughly 17% while the biotech benchmark (XBI — SPDR S&P Biotech ETF) gained about 68%, a gap of 85 percentage points that far exceeds the 30-point trigger threshold for companies with negative absolute returns; the five-year picture is equally poor, so the policy's longer-track-record mitigant does not apply, and a vote against is warranted.
For Analysis
Mr. Germano is a new nominee who has not yet joined the board, so the 24-month new-director exemption applies and no TSR trigger can fire; he brings over 30 years of relevant pharmaceutical leadership experience, including senior roles at Pfizer and multiple biotech boards, making him a qualified addition to the slate.
Mr. Ignelzi joined the board in April 2026 and is therefore exempt from the TSR trigger under the 24-month new-director exemption; he is a credentialed CFO with extensive biotech and pharma finance experience, providing relevant financial expertise to the board.
Mr. Philip joined the board in April 2025, which is within the 24-month new-director exemption window, so no TSR trigger applies; he has deep life sciences leadership experience including serving as CEO of two biotech companies, making him a qualified director.
Of the four Class III nominees, three (Germano, Ignelzi, Philip) receive FOR votes — two are brand-new nominees never previously on the board and one joined within the past 24 months, all qualifying for the new-director exemption from the stock-performance trigger. Dr. Wicki, a director since 2017 whose full tenure overlaps the severe underperformance period (Harmony stock -17% vs. XBI +68% over three years, an 85-percentage-point gap that far exceeds the 30-point threshold), receives an AGAINST vote. The five-year picture offers no relief, as the gap is similarly large, so the longer-track-record mitigant does not apply.
Say on Pay
✗ AGAINSTCEO
Jeffrey M. Dayno, M.D.
Total Comp
$7,899,535
Prior Support
97.6%%
The CEO received total compensation of approximately $7.9 million in 2025 — composed of a $744K base salary, a $558K annual cash bonus, and roughly $6.6 million in stock options and restricted stock awards — which is high relative to typical benchmarks for a CEO at a $1.6 billion specialty pharmaceutical company. More critically, the pay-for-performance alignment check fails: Harmony's stock has declined about 17% over the past three years while the biotech benchmark (XBI — SPDR S&P Biotech ETF) gained roughly 68%, an 85-percentage-point gap, yet executives received above-target incentive pay and large equity grants during this period. Although the prior say-on-pay vote received 97.6% support in 2023 (no concern there), the policy requires a NO vote when variable pay is above benchmark and the company underperforms its sector peers by more than 20 percentage points over three years, a condition clearly met here.
Auditor Ratification
✓ FORAuditor
Deloitte & Touche LLP
Tenure
9 yrs
Audit Fees
$1,587,000
Non-Audit Fees
$693,000
Deloitte has served as Harmony's auditor since 2017 (approximately nine years), well below the 25-year tenure threshold that would raise independence concerns; the non-audit fees (tax services of $693,000) represent about 44% of audit fees ($1,587,000), which is below the 50% threshold that would trigger a concern; and Deloitte is a Big 4 firm appropriate for a $1.6 billion market-cap company.
Overall Assessment
The 2026 Harmony Biosciences annual meeting presents three standard proposals: director elections, auditor ratification, and say-on-pay. The principal governance concern is severe stock underperformance — Harmony shares are down about 17% over three years while the biotech benchmark XBI gained 68% — which drives an AGAINST vote on the long-tenured director (Dr. Wicki) and an AGAINST vote on executive pay due to the disconnect between above-benchmark incentive compensation and shareholder returns; the three newer director nominees and the auditor ratification both pass policy screens cleanly.